Webinar | September 23, 2020
NeoGenomics lead scientist for Vectra Polaris studies, Sara Pollan, PhD, explains the process to successfully optimize and validate a custom 7-color opal panel for multiplex immunofluorescence using the Vectra Polaris platform, to successfully profile and quantify exhausted T-cells in head and neck squamous cell carcinoma. NeoGenomics is a leading oncology testing company for pharma services, providing comprehensive support from biomarker discovery through assay design and development on the Vectra Polaris platform.